 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- |||| itepekimab (SAR440340) / Sanofi, Regeneron
New P2 trial: Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPD (EUDRACT) - Nov 23, 2021
P2, N=109, Ongoing, Sponsor: Sanofi-Aventis Recherche & Developpement
- || itepekimab (SAR440340) / Sanofi, Regeneron
Clinical, Journal: Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. (Pubmed Central) - Nov 17, 2021
P2
Interleukin-33 blockade with itepekimab led to a lower incidence of events indicating a loss of asthma control than placebo and improved lung function in patients with moderate-to-severe asthma. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03387852.).
- || Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, itepekimab (SAR440340) / Sanofi, Regeneron
Itepekimab und Risankizumab – neue Biologika bei Asthma in Phase 2 https://t.co/AEhCQNrbOi via @medscape (Twitter) - Nov 11, 2021
- |||| itepekimab (SAR440340) / Sanofi, Regeneron
Clinical: Visual Abstract: Efficacy and Safety of Itepekimab for Moderate-to-Severe Asthma https://t.co/7mldcsSaeW (Twitter) - Nov 3, 2021
- ||| itepekimab (SAR440340) / Sanofi, Regeneron
Itepekimab Interleukin 33 (!) antagonist Shoot… that means i should know something about interleukins 13-32 I also just learned IL33 is called alarmin This is indeed alarmin! (Twitter) - Oct 30, 2021
- |||||| itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment open: AERIFY-2: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Feb 20, 2021
P3, N=1170, Recruiting, Sponsor: Sanofi
(Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03387852.). Not yet recruiting --> Recruiting
- |||||||||| itepekimab (SAR440340) / Sanofi, Regeneron
New P3 trial: AERIFY-2: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Feb 11, 2021
P3, N=1170, Not yet recruiting, Sponsor: Sanofi
- |||||||||| itepekimab (SAR440340) / Sanofi, Regeneron
New P3 trial: AERIFY-1: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jan 7, 2021
P3, N=930, Recruiting, Sponsor: Sanofi
- ||| itepekimab (SAR440340) / Sanofi, Regeneron
Trial completion: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 10, 2020
P2b, N=129, Completed, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion, Monotherapy: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 8, 2020
P2a, N=206, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- SAR440340 / Sanofi, Regeneron
[VIRTUAL] SAR440340, An Anti-IL-33 Monoclonal Antibody, Demonstrated a Significant Reduction of LOAC Events and Improved Pre-BD FEV1 in Patients with Moderate to Severe Asthma: Results from the Phase 2 Proof of Concept Study (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_1290;
SAR440340 significantly reduced the proportion of patients with LOAC events vs. placebo, improved pre-BD FEV1, and was generally well tolerated in moderate-to-severe asthma patients after 12 weeks of treatment. Dupilumab effects on LOAC and pre-BD FEV 1 were consistent with previous dupilumab studies.
- ||| itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment closed, Enrollment change: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Apr 19, 2020
P2b, N=129, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Dupilumab effects on LOAC and pre-BD FEV 1 were consistent with previous dupilumab studies. Recruiting --> Active, not recruiting | N=300 --> 129
- ||| itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Apr 19, 2020
P2a, N=205, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting | N=300 --> 129 Recruiting --> Active, not recruiting | Trial completion date: Jan 2021 --> Jul 2020 | Trial primary completion date: Aug 2020 --> Mar 2020
- SAR440340 / Sanofi, Regeneron
SAR440340, An Anti-IL-33 Monoclonal Antibody, Demonstrated a Significant Reduction of LOAC Events and Improved Pre-BD FEV1 in Patients with Moderate to Severe Asthma: Results from the Phase 2 Proof of Concept Study (PENNSYLVANIA CONVENTION CENTER, Hall G (100 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_3332;
SAR440340 significantly reduced the proportion of patients with LOAC events vs. placebo, improved pre-BD FEV1, and was generally well tolerated in moderate-to-severe asthma patients after 12 weeks of treatment. Dupilumab effects on LOAC and pre-BD FEV1 were consistent with previous dupilumab studies.
- ||||| itepekimab (SAR440340) / Sanofi, Regeneron
New P2 trial: Dose-ranging study to assess the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthma Estudio de b (EUDRACT) - Mar 7, 2020
P2, N=1120, Ongoing, Sponsor: Sanofi-Aventis Recherche & Developpement
- |||| itepekimab (SAR440340) / Sanofi, Regeneron
Trial completion: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Feb 27, 2020
P2, N=343, Completed, Sponsor: Sanofi
Dupilumab effects on LOAC and pre-BD FEV1 were consistent with previous dupilumab studies. Active, not recruiting --> Completed
- || itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion: Study of REGN3500 and Dupilumab in Patients With Asthma (clinicaltrials.gov) - Jan 18, 2020
P1, N=32, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion date, Trial primary completion date, Monotherapy: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 24, 2019
P2a, N=280, Recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Aug 2020 --> Jan 2021 | Trial primary completion date: Mar 2020 --> Aug 2020
- SAR440340 / Sanofi, Regeneron
IL-33 blockade prevents exacerbations in a model of chronic airway inflammation by blunting persistent inflammation and remodeling (6C) - Aug 26, 2019 - Abstract #ERS2019ERS_4114;
Trial completion date: Aug 2020 --> Jan 2021 | Trial primary completion date: Mar 2020 --> Aug 2020 By normalizing the levels of key inflammatory and remodeling mediators, including ones that persist after cessation of HDM exposure, IL-33 blockade with REGN3500 is able to prevent the progression to a more severe phenotype, ameliorate lung function, and prevent exacerbations.
- | itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion, Combination therapy: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (clinicaltrials.gov) - Aug 18, 2019
P2, N=301, Completed, Sponsor: Sanofi
By normalizing the levels of key inflammatory and remodeling mediators, including ones that persist after cessation of HDM exposure, IL-33 blockade with REGN3500 is able to prevent the progression to a more severe phenotype, ameliorate lung function, and prevent exacerbations. Active, not recruiting --> Completed
- | itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Trial primary completion date, Combination therapy: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (clinicaltrials.gov) - Aug 1, 2019
P2, N=297, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Trial primary completion date: Apr 2019 --> Sep 2019
- | itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment closed: Study of REGN3500 and Dupilumab in Patients With Asthma (clinicaltrials.gov) - Jul 18, 2019
P1, N=32, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Apr 2019 --> Sep 2019 Recruiting --> Active, not recruiting
- ||| itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment closed: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Apr 26, 2019
P2, N=343, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment closed, Combination therapy: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (clinicaltrials.gov) - Jan 25, 2019
P2, N=297, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || itepekimab (SAR440340) / Sanofi, Regeneron
Trial primary completion date: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jan 23, 2019
P2, N=340, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2020 --> Dec 2019
- |||| itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment open, Trial primary completion date: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 19, 2018
P2b, N=300, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Apr 2020 --> Dec 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2019 --> Mar 2020
- |||| itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment open, Monotherapy: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 19, 2018
P2a, N=280, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- || itepekimab (SAR440340) / Sanofi, Regeneron
Trial completion, Trial primary completion date: Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma (clinicaltrials.gov) - Dec 12, 2018
P1, N=23, Completed, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Aug 2018
- | itepekimab (SAR440340) / Sanofi, Regeneron
New P2b trial: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 13, 2018
P2b, N=300, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- | itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
New P2a trial, Monotherapy: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 9, 2018
P2a, N=280, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion date, Trial primary completion date, Combination therapy: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (clinicaltrials.gov) - Oct 16, 2018
P2, N=240, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Aug 2018 Trial completion date: Dec 2019 --> Aug 2019 | Trial primary completion date: Sep 2019 --> Apr 2019
- |||| itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment open: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jul 19, 2018
P2, N=340, Recruiting, Sponsor: Sanofi
Trial completion date: Dec 2019 --> Aug 2019 | Trial primary completion date: Sep 2019 --> Apr 2019 Not yet recruiting --> Recruiting
- ||||| itepekimab (SAR440340) / Sanofi, Regeneron
New P2 trial: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jun 5, 2018
P2, N=340, Not yet recruiting, Sponsor: Sanofi
- itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Study of REGN3500 and Dupilumab in Patients With Asthma (clinicaltrials.gov) - Mar 22, 2018
P1, N=38, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Aug 2018 --> Jan 2020 | Initiation date: Apr 2017 --> Jul 2017 | Trial primary completion date: Aug 2018 --> Apr 2019
- itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment closed, Trial primary completion date, IO biomarker: Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma (clinicaltrials.gov) - Mar 22, 2018
P1, N=23, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Aug 2018 --> Jan 2020 | Initiation date: Apr 2017 --> Jul 2017 | Trial primary completion date: Aug 2018 --> Apr 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2018 --> May 2018
- |||| itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment open, Combination therapy: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (clinicaltrials.gov) - Mar 21, 2018
P2, N=240, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2018 --> May 2018 Not yet recruiting --> Recruiting
- ||||| itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial, Combination therapy: Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (clinicaltrials.gov) - Jan 2, 2018
P2, N=240, Not yet recruiting, Sponsor: Sanofi
- itepekimab (SAR440340) / Sanofi, Regeneron
Trial primary completion date, IO biomarker: Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma (clinicaltrials.gov) - Nov 21, 2017
P1, N=24, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2018 --> Nov 2018
- itepekimab (SAR440340) / Sanofi, Regeneron
Trial primary completion date, IO biomarker: Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma (clinicaltrials.gov) - Nov 17, 2017
P1, N=24, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Feb 2018 --> Nov 2018 Trial primary completion date: Jul 2017 --> Feb 2018
- | itepekimab (SAR440340) / Sanofi, Regeneron
Trial completion: A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects (clinicaltrials.gov) - Nov 8, 2017
P1, N=40, Completed, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Jul 2017 --> Feb 2018 Active, not recruiting --> Completed
- itepekimab (SAR440340) / Sanofi, Regeneron
Trial primary completion date: A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects (clinicaltrials.gov) - May 23, 2017
P1, N=40, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Sep 2017
- | itepekimab (SAR440340) / Sanofi, Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
New P1 trial: Study of REGN3500 and Dupilumab in Patients With Asthma (clinicaltrials.gov) - Apr 13, 2017
P1, N=38, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment open, IO biomarker: Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma (clinicaltrials.gov) - Jan 19, 2017
P1, N=24, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Feb 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- itepekimab (SAR440340) / Sanofi, Regeneron
Enrollment closed, Enrollment change: A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects (clinicaltrials.gov) - Jan 13, 2017
P1, N=40, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=31 --> 40
- | itepekimab (SAR440340) / Sanofi, Regeneron
New P1 trial, IO biomarker: Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma (clinicaltrials.gov) - Dec 21, 2016
P1, N=24, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- | itepekimab (SAR440340) / Sanofi, Regeneron
New P1 trial: A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects (clinicaltrials.gov) - Nov 8, 2016
P1, N=31, Recruiting, Sponsor: Regeneron Pharmaceuticals